Ferritin drug carrier (FDC) for tumor targeting therapy.,Journal of Controlled Release

当前位置： X-MOL 学术 › J. Control. Release › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Ferritin drug carrier (FDC) for tumor targeting therapy.
Journal of Controlled Release ( IF 10.5 ) Pub Date : 2019-09-05 , DOI: 10.1016/j.jconrel.2019.09.002
Jiuyang He ₁ , Kelong Fan ₂ , Xiyun Yan ₃

Affiliation

Ferritin is an iron storage protein that plays a key role in iron homeostasis and anti-oxidation of cells. Due to its unique architecture of 24 self-assembling subunits and hollow cavity capable of encapsulating drugs, and an outer surface that can be modified genetically and chemically for additional functionality, ferritin has recently emerged as a promising drug delivery vehicle. Recent research demonstrated that unmodified human heavy chain ferritin binds to its receptor, transferrin receptor 1 (TfR1), in different types of tumor tissues, including lung and breast cancer, thus highlighting the potential use of ferritin for tumor-targeting applications. In this review, we consider the many favorable characteristics of ferritin drug carriers (FDCs) for tumor drug delivery. In particular, compared with antibody-drug conjugates (ADCs), ferritin exhibits superiority in a range of attributes, including drug loading ability, thermostability, and ease of production. Thus, the emergence of FDCs may be the next step in targeted cancer therapy.

中文翻译：

铁蛋白药物载体（FDC）用于肿瘤靶向治疗。

铁蛋白是一种铁存储蛋白，在铁稳态和细胞抗氧化中起关键作用。由于其独特的24个自组装亚基和能够封装药物的中空空腔的结构，以及可以通过基因和化学方法修饰以获得其他功能的外表面，铁蛋白最近已成为一种有前途的药物输送工具。最近的研究表明，未修饰的人重链铁蛋白在包括肺癌和乳腺癌在内的不同类型的肿瘤组织中与其受体转铁蛋白受体1（TfR1）结合，从而突显了铁蛋白在靶向肿瘤中的潜在用途。在这篇综述中，我们考虑了铁蛋白药物载体（FDC）对于肿瘤药物递送的许多有利特性。特别是，与抗体药物偶联物（ADC）相比，铁蛋白在包括药物装载能力，热稳定性和易生产性在内的一系列属性中均显示出优越性。因此，FDC的出现可能是靶向癌症治疗的下一步。

更新日期：2019-09-05

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南